At a Glance The FDA reversed its 2022 NMN ban in September 2025, allowing the $500 million ingredient back on the market ...

The Orphan Drug Act revolutionized rare disease treatment, yet rising costs and access issues challenge equitable health care solutions.

The CBN has approved a temporary two-month window allowing importers to use expired NAFDAC licences for Form M processing ...